Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,615,500 | 699,800 | 3,322,000 | 2,503,100 | 1,572,600 |
| Depreciation Amortization | 80,200 | 38,800 | 148,300 | 109,900 | 73,200 |
| Income taxes - deferred | -290,000 | -113,400 | -275,900 | -424,000 | -241,700 |
| Accounts receivable | -93,400 | -90,500 | -358,600 | -368,800 | -249,300 |
| Accounts payable and accrued liabilities | 71,300 | 35,700 | 120,800 | -39,100 | 30,800 |
| Other Working Capital | 384,300 | 138,900 | 340,800 | 431,700 | 350,900 |
| Other Operating Activity | 266,400 | 190,600 | 832,500 | 838,700 | 559,500 |
| Operating Cash Flow | $2,034,300 | $899,900 | $4,129,900 | $3,051,500 | $2,096,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -101,700 | -42,100 | -204,700 | -171,100 | -116,900 |
| Net Acquisitions | N/A | N/A | -295,900 | -295,900 | N/A |
| Purchase Of Investment | -2,390,800 | -1,841,500 | -692,700 | -465,600 | -237,900 |
| Sale Of Investment | 384,900 | 50,000 | 920,000 | 435,900 | 242,300 |
| Other Investing Activity | -29,900 | 0 | -47,800 | 0 | 0 |
| Investing Cash Flow | $-2,137,500 | $-1,833,600 | $-321,100 | $-496,700 | $-112,500 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -21,600 | -10,600 | -85,500 | -75,100 | -25,600 |
| Common Stock Issued | 72,800 | 14,200 | 186,300 | 134,700 | 98,100 |
| Common Stock Repurchased | -161,100 | -132,800 | N/A | 0 | 0 |
| Other Financing Activity | -167,500 | -165,500 | -168,500 | -167,500 | -120,200 |
| Financing Cash Flow | $-277,400 | $-294,700 | $-67,700 | $-107,900 | $-47,700 |
| Exchange Rate Effect | 22,000 | 12,000 | -29,200 | -70,000 | -31,800 |
| Beginning Cash Position | 10,512,000 | 10,512,000 | 6,800,100 | 6,800,100 | 6,800,100 |
| End Cash Position | 10,153,400 | 9,295,600 | 10,512,000 | 9,177,000 | 8,704,100 |
| Net Cash Flow | $-358,600 | $-1,216,400 | $3,711,900 | $2,376,900 | $1,904,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,034,300 | 899,900 | 4,129,900 | 3,051,500 | 2,096,000 |
| Capital Expenditure | -101,700 | -42,100 | -204,700 | -171,100 | -116,900 |
| Free Cash Flow | 1,932,600 | 857,800 | 3,925,200 | 2,880,400 | 1,979,100 |